

SmartPA Criteria Proposal

Drug/Drug Class:	Antifungals (Onychomycosis/Candidiasis), Oral PDL Edit
First Implementation Date:	November 9, 2005
Proposed Date:	April 18, 2023
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Onychomycosis is a fungal infection of the nails usually caused by trichophyton rubrum and trichophyton mentagrophytes. These dermatophytes feed on keratinized nail tissue and are normally confined to the nails; but occasionally spread to surrounding skin. The hallmarks of the disease are thickening, scaling, discoloration, and splitting of the nail bed. Without treatment, however, the nails can become so thick they press against the inside of the shoes, causing pressure, irritation, and pain. Onychomycosis is difficult to treat because nails grow slowly and receive very little blood supply. However, there have been recent advances in treatment options, including oral and topical medications. These medications are usually administered over a 3-month period, but because the nails grow very slowly it will typically take 6 months to a year for the nail to regain a healthy, clear, thin appearance. This class of oral antifungals includes agents for oropharyngeal candidiasis in adults and children. Effective therapy usually requires treatment for 7-14 days. Fluconazole is the agent of choice for prevention of oropharyngeal candidiasis in immunocompromised adults and children. At this time, this PDL Therapeutic Class does not include the oral antifungals that are used to treat serious fungal infections, including invasive aspergillosis.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Clotrimazole Troche Fluconazole Susp/Tabs Griseofulvin Susp Nystatin Susp/Tabs Terbinafine Tabs 	<ul style="list-style-type: none"> Diflucan® Griseofulvin Micro/Ultramicrosize Tabs Itraconazole Oravig® Sporanox®

Type of Criteria: ☒ Increased risk of ADE
☒ Appropriate Indications

☒ Preferred Drug List
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Antifungals (Onychomycosis/Candidiasis), Oral
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial of 1 preferred agent
 - Documented trial period of preferred agents
 - Documented ADE/ADR to preferred agents
- For itraconazole:
 - Documented diagnosis of proximal or distal, white, subungual onychomycosis, identified through:
 - KOH microscopic exam **OR**
 - Periodic Acid Schiff (PAS) **OR**
 - Fungal culture **OR**
 - Nail biopsy **AND**
 - > 30% nail plate involvement
 - Maximum approvable durations of therapy for onychomycosis:

Product	Strength/Dose	Duration of Therapy	Anatomic Location of Infection
Itraconazole	200 mg twice daily	1 week (3 weeks no therapy) for 3 cycles (pulse)	Fingernails
Itraconazole	200 mg once daily	12 weeks (or pulse)	Toenails

- For griseofulvin suspension: Clinical Consultant Review for participants aged 10 years or older

Denial Criteria

- Lack of adequate trial on required preferred agents
- For itraconazole: left ventricular dysfunction, such as congestive heart failure
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

X

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

6 months

References

- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: ANTI-INFECTIVES: Antifungals for Onychomycosis", Gainwell Technologies; Last updated February 20, 2023.

SmartPA PDL Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.

- Evidence-Based Medicine and Fiscal Analysis: “Therapeutic Class Review: ANTI-INFECTIVES: Antifungals for Thrush”, Gainwell Technologies; Last updated February 22, 2023.
- Evidence-Based Medicine Analysis: “Anti-infectives: Antifungals for onychomycosis and thrush”, UMKC-DIC; Last updated January 2023.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.

DRAFT